However, the extremely high‐affinity interaction between Aβ42 and α7 nAChR, as well as the fact that this receptor becomes rapidly desensitized, makes the development of an anti‐AD drug that directly targets α7 nAChR quite challenging [115]. Here, CHRNA7 is linked to Alzheimer disease.